A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.

Inclusion Criteria: * Histologically confirmed diagnosis of non-myeloid malignancy * Baseline hemoglobin value of less than or equal to 11 g/dL unrelated to transfusion * Patients must not be receiving or planning to receive chemotherapy or radiotherapy within the 16-week study period. However, patients receiving hormonal therapy or non-myelosuppressive therapies are allowable * Female patients with reproductive potential must have a negative serum pregnancy test at screening. Exclusion Criteria: * Uncontrolled hypertension * History (within 6 months) of uncontrolled cardiac arrhythmias, or history of pulmonary emboli, deep vein thrombosis, ischemic stroke, other arterial or venous thrombotic events (excluding superficial thromboses), or known history of chronic coagulation disorder * Transfusion within 28 days prior to first dose * Planned chemotherapy or radiation during study and no prior chemotherapy within 8 weeks or radiation within 4 weeks of study entry * No prior treatment with Epoetin alfa or any other erythropoietic agent within the previous two months